JAMA Dermatology : Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus
Interview with Aimee S. Payne, MD, PhD, author of Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - October 23, 2019 Category: General Medicine Source Type: podcasts
MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed By Maintenance Therapy In Relapsed/Refractory NHL.
David Andorsky MD Of US Oncology Research Discusses MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed By Maintenance Therapy In Relapsed/Refractory NHL.
Author: Annual-Meeting
Added: 06/03/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 3, 2019 Category: Cancer & Oncology Source Type: podcasts
Can A Rituximab Biosimilar Replace Rituximab
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Can A Rituximab Biosimilar Replace Rituximab. At The 60th ASH Ann...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
Potential Side Effects From Venetoclax + Rituximab In CLL
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Potential Side Effects From Venetoclax + Rituximab In CLL. At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
Rituximab Biosimilars In Follicular Lymphoma
Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses Rituximab Biosimilars In Follicular Lymphoma. A...
Author: obr
Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR
Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR. At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: obr
Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
Treating CLL Patients With Venetoclax And Rituximab
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Treating CLL Patients With Venetoclax And Rituximab. At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: obr
Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
Better To Combine Ibrutinib With Rituximab?
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology,<br />Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Discusses Bett...
Author: imedex
Added: 11/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 28, 2018 Category: Cancer & Oncology Source Type: podcasts
The switch to biosimilar rituximab at UCH: 12 months on
At the 2018 British Oncology Pharmacy Association (BOPA) Annual Symposium, Simon Cheesman, MRPharmS, of University College London, London, UK, presented the experiences at University College Hospital ...
Author: VJOncology
Added: 10/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 15, 2018 Category: Cancer & Oncology Source Type: podcasts
Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL
Exciting updates on obinutuzumab were presented at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Final analysis results from the CLL11 study (NCT01010...
Author: VJHemOnc
Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts
Meletios Exciting new therapy for Waldenstrms macroglobulinemia: ibrutinib plus rituximab
Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenstrms macroglobulinemia (WM) were presented at the 23rd congress of the European Hematology As...
Author: VJHemOnc
Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts
Exciting new therapy for Waldenstrms macroglobulinemia: ibrutinib plus rituximab
Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenstrms macroglobulinemia (WM) were presented at the 23rd congress of the European Hematology As...
Author: VJHemOnc
Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts
Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?
The MURANO study (NCT02005471) is a Phase III trial looking at rituximab in combination with either bendamustine or venetoclax for the treatment of refractory chronic lymphocytic Leukemia (CLL). A key...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Rituximab maintenance key to outcome improvement in mantle cell lymphoma
Mantle cell lymphoma (MCL) outcomes have improved in recent years as a result of an influx of improved treatments, including rituximab, high dose Ara-C and stem cell transplant. As Marek Trneny, MD, P...
Author: VJHemOnc
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Results of RELEVANCE: frontline rituximab-lenalidomide for follicular lymphoma
Results of the Phase III RELEVANCE trial (NCT01476787) of rituximab-lenalidomide for untreated follicular lymphoma were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chic...
Author: VJHemOnc
Added: 07/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 30, 2018 Category: Cancer & Oncology Source Type: podcasts
